BridgeBio Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
21analysts covering
FY Revenue (est.)
$1Bnext fiscal year
FY EPS (est.)
-$2.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| BBP-418 PDUFA Target Action Date | 27 Nov 2026 |
| Convertible Notes Conversion Eligibility Date | 15 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Attruby (acoramidis) U.S. Net Product Revenue Quarterly180.6MTarget: 4000000000 peak annual sales
Total Cash, Cash Equivalents, and Marketable Securities Quarterly940.2MTarget: Maintain sufficient runway for multiple commercial launches
Attruby New Patient Starts Quarterly6.1KTarget: Continued sequential growth in treatment-naïve and switch patients
Watch Items
- BBP-418 FDA Approval for LGMD2I/R9Trigger: PDUFA target action date of November 27, 2026Action: Monitor FDA communication, prepare commercial launch infrastructure, and track potential Priority Review Voucher issuance.
- Encaleret NDA Review for ADH1Trigger: FDA acceptance of NDA submitted in May 2026Action: Track regulatory review timeline, potential priority review designation, and prepare for early 2027 U.S. launch.
- Infigratinib NDA Submission for AchondroplasiaTrigger: Planned submission in Q3 2026Action: Verify completion of NDA filing and monitor subsequent FDA acceptance and review timeline.
- Convertible Notes Maturity and Dilution RiskTrigger: Convertible notes due March 15, 2027 ($550 million) with conversion option starting December 15, 2026Action: Assess balance sheet liquidity, potential refinancing, or dilutive impact of note conversions.
Research as of 2 Sep 2026